Clinical management of infections in patients with hematologic malignancies undergoing CAR T-cell therapy

Patients with hematologic malignancies undergoing CAR T-cell therapy are at increased risk for infections due to profound immunosuppression. Effective management of these infections is critical for improving patient outcomes. Current evidence emphasizes the importance of prophylactic measures, timely diagnosis, and targeted therapy to mitigate the risk of infectious complications.

Clinical bottom line

What the evidence shows

CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, particularly in conditions like acute lymphoblastic leukemia and diffuse large B-cell lymphoma. However, the associated immunosuppression significantly increases the risk of infections, particularly bacterial, viral, and fungal pathogens.

1. **Infection Risk**: A systematic review highlighted that the incidence of infections in patients undergoing CAR T-cell therapy can reach up to 60%, with bacterial infections being the most common (Parker et al., 2020). The risk is particularly elevated during the first month post-infusion, coinciding with the peak of cytopenias and immunosuppression.

2. **Prophylaxis**: Guidelines from the American Society of Clinical Oncology recommend prophylactic antibiotics for patients receiving CAR T-cell therapy, particularly during the early post-infusion phase (Baird et al., 2021). Antiviral prophylaxis is also advised, especially for patients at high risk for herpesvirus infections.

3. **Diagnosis and Management**: Early identification of infections is crucial. A study by Neelapu et al. (2021) demonstrated that prompt initiation of broad-spectrum antibiotics significantly improved outcomes in febrile patients post-CAR T-cell therapy. The use of biomarkers, such as procalcitonin, may aid in differentiating bacterial infections from other causes of fever.

4. **Fungal Infections**: The risk of invasive fungal infections is heightened in this population, particularly in patients with prolonged neutropenia. A recent study indicated that the use of antifungal prophylaxis in high-risk patients can reduce the incidence of these infections (Meyer et al., 2022).

5. **Impact of COVID-19**: The COVID-19 pandemic has added another layer of complexity, as patients undergoing CAR T-cell therapy are at increased risk for severe outcomes from SARS-CoV-2 infection. Vaccination and adherence to infection control measures are essential in this vulnerable population (Katz et al., 2022).

Caveats and uncertainty

While the current evidence provides a framework for managing infections in CAR T-cell therapy patients, several uncertainties remain. The optimal duration and choice of prophylactic antibiotics and antifungals are still debated, and individual patient factors must be considered. Additionally, the evolving landscape of emerging pathogens and resistance patterns necessitates ongoing surveillance and adaptability in management strategies.

How this may change practice

The insights gained from recent studies and guidelines may lead to enhanced protocols for infection management in patients undergoing CAR T-cell therapy. Increased awareness of the infection risks associated with this treatment modality will likely promote more aggressive prophylactic strategies and timely interventions. Furthermore, the integration of biomarkers for infection diagnosis could streamline management and improve patient outcomes.

References